Unknown

Dataset Information

0

SuperFi-Cas9 exhibits remarkable fidelity but severely reduced activity yet works effectively with ABE8e.


ABSTRACT: Several advancements have been made to SpCas9, the most widely used CRISPR/Cas genome editing tool, to reduce its unwanted off-target effects. The most promising approach is the development of increased-fidelity nuclease (IFN) variants of SpCas9, however, their fidelity has increased at the cost of reduced activity. SuperFi-Cas9 has been developed recently, and it has been described as a next-generation high-fidelity SpCas9 variant, free from the drawbacks of first-generation IFNs. In this study, we characterize the on-target activity and the off-target propensity of SuperFi-Cas9 in mammalian cells, comparing it to first-generation IFNs. SuperFi-Cas9 demonstrates strongly reduced activity but high fidelity features that are in many aspects similar to those of some first-generation variants, such as evo- and HeFSpCas9. SuperFi-cytosine (CBE3) and -adenine (ABE7.10) base editors, as well as SuperFi-prime editor show no meaningful activity. When combined with ABE8e, SuperFi-Cas9, similarly to HeFSpCas9, executes DNA editing with high activity as well as high specificity reducing both bystander and SpCas9-dependent off-target base editing.

SUBMITTER: Kulcsar PI 

PROVIDER: S-EPMC9652449 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

SuperFi-Cas9 exhibits remarkable fidelity but severely reduced activity yet works effectively with ABE8e.

Kulcsár Péter István PI   Tálas András A   Ligeti Zoltán Z   Krausz Sarah Laura SL   Welker Ervin E  

Nature communications 20221111 1


Several advancements have been made to SpCas9, the most widely used CRISPR/Cas genome editing tool, to reduce its unwanted off-target effects. The most promising approach is the development of increased-fidelity nuclease (IFN) variants of SpCas9, however, their fidelity has increased at the cost of reduced activity. SuperFi-Cas9 has been developed recently, and it has been described as a next-generation high-fidelity SpCas9 variant, free from the drawbacks of first-generation IFNs. In this study  ...[more]

Similar Datasets

| S-EPMC10374439 | biostudies-literature
| S-EPMC11662675 | biostudies-literature
2012-06-19 | E-GEOD-33215 | biostudies-arrayexpress
2012-06-20 | GSE33215 | GEO
| S-EPMC9398351 | biostudies-literature
| S-EPMC4108031 | biostudies-literature
| S-EPMC9352718 | biostudies-literature
| S-EPMC5902734 | biostudies-literature
| S-EPMC10018339 | biostudies-literature